

## ESPS PEER REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**ESPS manuscript NO:** 12662

**Title:** Anti-EGFR MoAbs as first line treatment in metastatic colorectal cancer: A meta-analysis

**Reviewer code:** 00058361

**Science editor:** Ya-Juan Ma

**Date sent for review:** 2014-07-20 19:10

**Date reviewed:** 2014-08-04 04:51

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair		BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Existing	<input checked="" type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

## COMMENTS TO AUTHORS

KRAS should be defined in abstract – writing in full. Abstract: Bevacizumab should be defined in abstract – for example ... the angiogenesis inhibitor Bevacizumab ... Pg.3 This truth has been proved ... change into ... Those observations have been shown beneficial .... M&M: ... When the same patient population was used in several publications, only the most recent, largest or complete study was included in the meta-analysis. .... This needs to be refined and more detail provided: most recent (i.e., past 6 months?), how do you define largest (???? More than 100 patients??), similarly, ... most complete study???(what do you mean with this????). After exclusion of duplicate and irrelevant studies (Figure1), .... As per above, how did you define this? Materials and Methods need more detail (i.e., elaborate on ....). Also, you need a statement that all data analysed are freely available as supplementary data on the WJG website or can be provided on request. However, patients with wild-type KRAS seemed not to benefit from anti-EGFR MoAbs with oxaliplatin-based chemotherapy as first line treatment. .... This needs to be underpinned by referring to the corresponding figure or table; or even with statistical evidence at the end of the sentence/statement. The main downstream signaling pathway of EGFR regulates crucial biological activities such as cell differentiation, cell survival, cell proliferation and cell migration. ... this sentence is in the need of literature reference(s). and bevacizumab using. .... Change into and bevacizumab treatment